Showing results (821-830 of 844) with videos related to

Sort By:
Pageof 85
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research StudyAnita D'Souza, Angela Dispenzieri, Baldeep Wirk, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 4, 2015
New cancers after autotransplantations for multiple myelomaAnuj Mahindra, Girindra Raval, Paulette Mehta, et al.
JCI Insight|April 20, 2018
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myelomaAlfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, et al.
The Journal of Allergy and Clinical Immunology|January 17, 2020
Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2)Pui Y Lee, Erinn S Kellner, Yuelong Huang, et al.
Medrxiv : the Preprint Server for Health Sciences|March 11, 2024
T cell and autoantibody profiling for primary immune regulatory disordersEmily M Harris, Sarah Chamseddine, Anne Chu, et al.
The Journal of Allergy and Clinical Immunology|June 20, 2025
T-cell and autoantibody profiling for primary immune regulatory disordersEmily M Harris, Sarah Chamseddine, Anne Chu, et al.
Leukemia|February 26, 2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trialsMaria Gavriatopoulou, Ajai Chari, Christine Chen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2014
Older patients with myeloma derive similar benefit from autologous transplantationManish Sharma, Mei-Jie Zhang, Xiaobo Zhong, et al.
Nature Medicine|January 24, 2024
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Joseph A Fraietta, James N Gerson, et al.
Nature Medicine|July 21, 2015
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myelomaAaron P Rapoport, Edward A Stadtmauer, Gwendolyn K Binder-Scholl, et al.
Pageof 85